SCHEMBL11919909

SCHEMBL11919909

Fc1ccc(-n2c(SCc3nc(-c4ccc(Cl)cc4)no3)nnc2-c2ccncc2)cc1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.84
LMNA P02545 2/20 0.84
ALDH1A1 P00352 2/20 0.84
MEN1 O00255 1/20 0.84
KMT2A Q03164 1/20 0.84
HTT P42858 3/20 0.82
TNKS2 Q9H2K2 9/20 0.79
MAPT P10636 5/20 0.79
THRB P10828 2/20 0.79
NPSR1 Q6W5P4 3/20 0.75
MAPK1 P28482 2/20 0.73
USP2 O75604 1/20 0.73
TSHR P16473 1/20 0.71
TNKS O95271 4/20 0.70
SMN1; SMN2 Q16637 2/20 0.70
CYP3A4 P08684 1/20 0.67
CYP2D6 P10635 1/20 0.67
CYP2C9 P11712 1/20 0.67
SULT2A1 Q06520 1/20 0.67
NR5A1 Q13285 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11919901 0.91 TP53 (1.00) TP53LMNAALDH1A1MEN1KMT2A
SCHEMBL13048271 0.91 TP53 (0.84) TP53LMNAALDH1A1MEN1KMT2A
SCHEMBL11919919 0.89 ALDH1A1 (0.73) TP53LMNAALDH1A1MEN1KMT2A
SCHEMBL11919903 0.88 TP53 (1.00) TP53LMNAALDH1A1MEN1KMT2A
SCHEMBL11919942 0.82 LMNA (0.78) TP53LMNAALDH1A1MEN1KMT2A
SCHEMBL11919979 0.82 NPSR1 (0.87) TP53LMNAALDH1A1MEN1KMT2A
SCHEMBL11919932 0.82 LMNA (0.74) TP53LMNAALDH1A1MEN1KMT2A
SCHEMBL13046998 0.82 NPSR1 (0.90) TP53LMNAALDH1A1MEN1KMT2A
SCHEMBL11919996 0.81 ALDH1A1 (0.80) TP53LMNAALDH1A1MEN1KMT2A
SCHEMBL11919898 0.80 TNKS2 (1.00) TP53LMNAALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 US disclosed
US-8883827-B2 Azole derivatives as WTN pathway inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2014-11-11 US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 US disclosed
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors OSLO UNIVERSITY HOSPITAL HF (NO) 2012-08-16 US disclosed
WO-2010139966-A1 AZOLE DERIVATIVES AS WTN PATHWAY INHIBITORS OSLO UNIVERSITY HOSPITAL HF (NO) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208828-A1 Azole Derivatives as WTN Pathway Inhibitors WNT1, AXIN2, WNT3 TP53 53/4885LMNA 1015/4885ALDH1A1 1296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.